font size
Sign inprintPrint

VENTURE CAPITAL:

Privately Held Life Sciences Companies Raise $1.5B so Far in April

Biotechs rake in $188 million in series B cash in short week before Easter.


Though Wall Street is turning cautious on biotech, privately held life sciences companies are experiencing a boon in funding for their projects. Almost $1.5 billion in new capital has been committed to these companies during the first three weeks of April, with $1.2 billion of that raised by U.S. companies and almost $1 billion raised globally by companies developing therapeutics, diagnostics, and life sciences tools and technology. Read More
Other recent stories

Sign Up to recevie the Burrill Weekly Brief


Follow burrillreport on Twitter